TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Referred pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) in the Dose Escalation Phase
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase 2 Dose (RPTD) Determined in the Dose Escalation Phase
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving Clinical Response (PRO2 Score ≤ 8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Endoscopic Response (≥ 50% Reduction From Baseline SES-CD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants That Tolerated Rapid Oral Peanut Desensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in 8-hydroxy-2'-Deoxyguanosine (8OHdG) Immunostaining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Standard Drinks Per Assessment Period on Timeline Followback (TLFB)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Heavy Drinking Days Per Assessment Period on Timeline Followback (TLFB)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Post-treatment ADHD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-treatment functional impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Comparison of Q-tip test and clip strip test results with surgical results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free rate at 6-month
Endpoint domain: Mortality/survival
Primary endpoint: Human platelet aggregation induced by Platelet Activating Factor (PAF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: proportion of men experiencing specific safety events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean percentage of viable clinically-significant prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Absence of Anterior Chamber Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Absence of Ocular Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Running Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PROMIS-Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Development of early onset pneumonia or ventilator associated pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of AVP and vasopressin V1 receptor expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Stage of ovarian neoplasms graded by histology assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intratumoral vascularization through Doppler ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Enhancement of Mitochondrial Function in Skeletal Muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Circulating NT-proANP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Grade 3 or higher Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: 1-year disease free survival percentage
Endpoint domain: Mortality/survival
Primary endpoint: Carriage of Pneumococcal Serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence of acute cellular rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Breakpoint of Drug Purchase Tasks (DPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breakpoint of Multiple Choice Procedure (MCP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effort for Product Puffs With the Progressive Ratio Task (PRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of subjects with response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in symptoms of inflammation of the periodontium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First PCR-detectable Malaria Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: FA (Fractional Anisotropy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MTR (magnetization transfer ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: T2 (Transverse relaxation time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Patients Who have Greatly Improved or Improved on the 4-Point Treatment Benefit Scale (TBS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Number of Urinary Incontinence Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of microRNA expression in skeletal muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Responder Rate at End of Study (EOS) Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial metabolic response (PMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete metabolic response (CMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progressive metabolic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Atrial Fibrillation Termination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Free From Recurrent AT/AF on no AAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Free From Recurrent AT/AF With no or Some AAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-operative endoscopic appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-Operative SNOT-22
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Determination of Alzheimer's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adherence with instructions for use of Ventavis®
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cmax of Supaglutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of Supaglutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of Supaglutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t½ of Supaglutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Alopecia Tool (SALT) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychosocial progress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: point prevalence of clinical dissociation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breathlessness, Cough and Sputum Scale (BCSS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AUC of Pupillary Light Reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of grade III and above radiation-reduced esophagitis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of grade III and above radiation-reduced pneumonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Depression Measure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: First myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in mean Plasma Phe levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cervical flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with a Successful Index Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants Without an Index Procedure Related Safety Incident
Endpoint domain: Adverse events/effects
Primary endpoint: Participants understanding of atopic dermatitis and homecare regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to Extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in BRIEF-A GEC T-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of SOM230
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in overeating (Eating in the absence of hunger)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in child weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunological failure (CD4 cell count below 300/µl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cerebral Glucose Metabolic Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neuropsychological Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: plasma concentration of factors II, VII, IX, X, proteins S and C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in severity of consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in level of consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of (hypo) manic symptoms associated with a comorbid psychiatric disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of late-stage lung cancer at diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Onset of Axillary Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in recall capacity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Weight-for-height Z scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of seizure-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Achievement of seizure-free status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Toxicity according to NCI/NIH Common Toxicity Criteria
Endpoint domain: Adverse events/effects
Primary endpoint: Bone marrow cytogenetic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: overall mortality rate at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Short Physical Performance Battery (SPPB)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Timed Up and Go Test (TUG)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Birth at less than 37 weeks gestational age
Endpoint domain: Mortality/survival
Primary endpoint: Hypoglycemia monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reaction to efrin test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PONV Occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PONV Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of GDC-0032
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Singapore Modified - Mini Mental State Examination Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Clinical Dementia Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Rey Auditory Verbal Learning Test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Addiction remission
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Graft Loss or Death
Endpoint domain: Mortality/survival
Primary endpoint: Rate of healthcare utilisation based exacerbations of COPD
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: first occurrence of a non-fatal heart failure event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: < 15% reduction in echocardiography determined LVESV from baseline to 12-month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum Levels of Thalidomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Levels of Hydroxycloroquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-rating of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure treated to target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change from baseline Modified Ashworth Scale (MAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Progression to severe hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Partial Mayo Score: Change From Baseline Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mayo Score: Change From Baseline Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standardized Uptake Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of HIV infection in infants
Endpoint domain: Mortality/survival
Primary endpoint: Safety and tolerance of HIVIGLOB
Endpoint domain: Adverse events/effects
Primary endpoint: Change in HbA1c (Glycosylated haemoglobin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Susceptibility to tobacco initiation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the number of hypoglycemia-related driving mishaps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient reported satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Breastmilk Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Target heart wall thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart wall thickening fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Identification of elevated risk subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve at steady state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HV interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return Toward a Normal Fecal Bile Acid Pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: measurability of flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving target LDL goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients who consent to participate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Multidimensional Assessment of Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Physiological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With serum Creatine Phosphokinase Values greater than 5000 IU/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the mean Severity Scoring for Atopic Dermatitis (SCORAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants Who Correctly Used the Device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success Rate of the Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of malaria infection
Endpoint domain: Mortality/survival
Primary endpoint: Change in Standardized Photosensitivity Range (SPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neointimal coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: new stroke events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of LBH589
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Vineland™-II Adaptive Behavior Scale Two Domain Composite (2DC) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Completion rates of nCCR
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Visit frequency throughout nCCR treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Visit duration throughout nCCR treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in 24-hour Mean Weighted Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood Phenylalanine control: Phe levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anthropometry: weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurence of Adverse Events [ Safety and tolerability]
Endpoint domain: Adverse events/effects
Primary endpoint: Score on the Juniper Asthma Control Questionnaire (ACQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in platelet function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of renal function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of potential COS elements
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: surgical stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postoperative hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central Sensitization Inventory (CSI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total number of joint bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Circadian rhythms of serum lipid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in SF12
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cutaneomuscular Reflex Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Paired motor unit recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Concentration (Cmax) of Pravastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of Pravastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Maximum Observed Concentration (Tmax) of Pravastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arterial stiffening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Markers of endothelial function, vascular inflammation and collagen synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Left Ventricular End-Systolic Volume Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in occurrence of local skin reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis of synchronous carcinomas and polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in tumor lesion diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes